A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma

Clinical Cancer Research

Volumn 16, Issue 11, 2010, Pages 3019-3027

  Ardalan, Bach ^a   Subbarayan, Pochi R ^a   Ramos, Yipsel ^b   Gonzalez, Michael ^b   Fernandez, Anthony ^b   Mezentsev, Dmitry ^a   Reis, Isildinha ^a   Duncan, Robert ^a   Podolsky, Lisa ^a   Lee, Kelvin ^c   Lima, Mayra ^a   Ganjei Azar, Parvin ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Biology   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ARSENIC TRIOXIDE; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB; THYMIDYLATE SYNTHASE;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; HERPES ZOSTER; HUMAN; INTESTINE OBSTRUCTION; LOADING DRUG DOSE; MONONUCLEAR CELL; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; SIDE EFFECT; SINUS TACHYCARDIA; SMALL INTESTINE OBSTRUCTION; TUMOR BIOPSY; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; OXIDES; THYMIDYLATE SYNTHASE;

EID: 77953100418     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2590     Document Type: Article

References (19)

1. Braun AH, Achterrath W, Wilke H, et al. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004;100:1558-1577
2. Wang TL, Diaz LA, Jr., Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 2004;101:3089-3094
3. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-108
4. Saltz LB, Cox JV, Blanke C, et al, Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. Subbarayan PR, Lee K, Ardalan B. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line ht29 in vitro re-sensitizing Cells to 5-FU. Anticancer Res. In press 2010;30.
7. Subbarayan PR, Lima M, Ardalan B. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 2007;46:557-561
8. Spicer DV, Ardalan B, Daniels JR, et al. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 1988;48:459-461 (Pubitemid 18045787)
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
10. Nouri K, Ricotti CA, Jr., Bouzari N, et al. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J Drugs Dermatol 2006;5:182-185
11. Bathe OF, Franceschi D, Livingstone AS, et al. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 1999;5:34-40. (Pubitemid 29108644)
12. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-3324
13. Shen L, Chen TX, Wang YP, et al. As2O3 induces apoptosis of the human B lymphoma cell line MBC-1. J Biol Regul Homeost Agents 2000;14:116-119
14. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-3860
15. Grad JM, Bahlis NJ, Reis I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-813
16. McCafferty-Grad J, Bahlis NJ, Krett N, et al. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther 2003;2:1155-1164
17. Frohlich E, Czarnocka B, Brossart P, et al. Antitumor effects of arsenic trioxide in transformed human thyroid cells. Thyroid 2008;18:1183-1193
18. Pettersson HM, Pietras A, Munksgaard PM, et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther 2009;8:160-170
19. Jason TL, Figueredo R, Ferguson PJ, et al. ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines. DNA Cell Biol 2008;27:229-240